Agios Pharmaceuticals AGIO today announced that
data from its lead programs were highlighted at the American Society of
Hematology (ASH) Annual Meeting this week in New Orleans.
Two presentations featured in vivo efficacy data in acute
myelogenous leukemia (AML) for the company's lead cancer metabolism
programs targeting IDH1 and IDH2 mutations. In AML and other cancers,
IDH1 and IDH2 mutations initiate and drive cancer growth by blocking
maturation of primitive cells. The data presented at ASH demonstrate
preclinical single agent and combination efficacy of Agios' IDH mutant
inhibitors in patient-derived primary models of AML. Agios also
presented
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in